Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (50%) |
| No statute on record | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DELPHINUS DOU YI | 2 | 0.0% | +0.0% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.6% | +17.0% |
| GIBBS, TERRA C | 1 | 64.1% | +10.6% |
| GREENE, IVAN A | 1 | 18.7% | +6.6% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17951842 | METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS | YU, DELPHINUS DOU YI | 17d overdue |
| 17935022 | NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX | GREENE, IVAN A | 22d |
| 18495687 | SIRNAS AGAINST KRAS AND RAF1 | YU, DELPHINUS DOU YI | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17713037 | Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | REYNOLDS, FRED H | 44d overdue |
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 6d |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 9d |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1637 | 1 |
| 1635 | 1 |
| 1619 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18495687 | SIRNAS AGAINST KRAS AND RAF1 | YU, DELPHINUS DOU YI | 1636 | §103 | Non-Final OA | 54d | Pending | Oct 26, 2023 |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Non-Final OA | 9d | Pending | Mar 24, 2023 |
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 1635 | Other | Non-Final OA | 6d | Pending | Mar 07, 2023 |
| 17951842 | METHODS FOR PREPARING NANOPARTICLE COMPOSITIONS CONTAINING HISTIDINE-LYSINE COPOLYMERS | YU, DELPHINUS DOU YI | 1636 | §103 | Non-Final OA | 17d overdue | Pending | Sep 23, 2022 |
| 17935022 | NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX | GREENE, IVAN A | 1619 | §103 | Final Rejection | 22d | Pending | Sep 23, 2022 |
| 17713037 | Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | REYNOLDS, FRED H | 1658 | Other | Final Rejection | 44d overdue | Pending | Apr 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial